ArticleNature2010
Drug discovery: How melanomas bypass new therapy.
Article in Nature, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Melanoma therapeutics: a literature review.Journal of biomedical research · 2022Article
- Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors.ACS omega · 2022Article
- Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?Frontiers in oncology · 2021Article
- Loss of miR-155 upregulates WEE1 in metastatic melanoma.Melanoma research · 2019Article
- CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.Oncotarget · 2018Article
- Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.Molecular cancer therapeutics · 2017Article
- Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling.Oncogene · 2016Article
- The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.Melanoma management · 2015Review
- Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet.Frontiers in oncology · 2015Review
- Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?BMC medicine · 2014Article
- Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine.Journal of leukemia (Los Angeles, Calif.) · 2013Article
- Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.The American journal of pathology · 2013Article
- A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.British journal of pharmacology · 2012Review
- Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.The EMBO journal · 2012Article
- Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.Bioscience reports · 2012Review
- Personalized medicine and cancer.Journal of personalized medicine · 2012Review
- Clonal evolution in cancer.Nature · 2012Review
- Drug repositioning for personalized medicine.Genome medicine · 2012Review
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.Nature genetics · 2011Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21164474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.